WEGENER'S GRANULOMATOSIS: LONG-TERM RESULTS OF TREATMENTILLUM P; THORLING K.1981; ANN. OTOL., RHINOL., LARYNGOL.; ISSN 0003-4894; USA; DA. 1981; VOL. 90; NO 3; PP. 231-235; BIBL. 14 REF.Article

OTOLOGICAL MANIFESTATIONS OF WEGENER'S GRANULOMATOSISILLUM P; THORLING K.1982; LARYNGOSCOPE; ISSN 0023-852X; USA; DA. 1982; VOL. 92; NO 7; PART. 1; PP. 801-804; BIBL. 14 REF.Article

THE CLINICAL USEFULNESS OF SERUM COPPER DETERMINATIONS IN HODGKIN'S DISEASE. A RETROSPECTIVE STUDY OF 241 PATIENTS FROM 1963-1973.THORLING EB; THORLING K.1976; CANCER; U.S.A.; DA. 1976; VOL. 38; NO 1; PP. 225-231; BIBL. 10 REF.Article

Late nervous system disorders in cured malignant lymphoma: a clinical and neuropathological studyVES TERBY, A; RESKE-NIELSEN, E; KRISTENSEN, I. B et al.Clinical neuropathology. 1988, Vol 7, Num 3, pp 134-138, issn 0722-5091Article

Factors for central nervous system involvement in non-Hodgkins-lymphomaKELDSEN, N; MICHALSKI, W; BENTZEN, S. M et al.Acta oncologica (Stockholm). 1996, Vol 35, Num 6, pp 703-708, issn 0284-186XArticle

Phase III trial of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) versus cisplatin, etoposide, bleomycin and prednisone (CisEBP) for the treatment of advanced non-Hodgkin's lymphoma of high grade malignancyANDERSEN, J; THORLING, K; BENTZEN, S. M et al.Acta oncologica (Stockholm). 1990, Vol 29, Num 8, pp 995-999, issn 0284-186XArticle

Incidence, clinicopathological features and outcome of primary central nervous system lymphomas : population-based data from a Danish lymphoma registryKROGH-JENSEN, M; D'AMORE, F; JENSEN, M. K et al.Annals of oncology. 1994, Vol 5, Num 4, pp 349-354, issn 0923-7534Article

Clinicopathological features and prognostic factors in extranodal non-hodgkin lymphomasD'AMORE, F; CHRISTENSEN, B. E; BACH, B et al.European journal of cancer : (1990). 1991, Vol 27, Num 10, pp 1201-1208Article

Non-Hodgkin's lymphoma in the elderlyD'AMORE, F; BRINCKER, H; CHRISTENSEN, B. E et al.Annals of oncology. 1992, Vol 3, Num 5, pp 379-386, issn 0923-7534Article

Long-term survival and development of secondary malignancies in patients with acute myeloid leukemia treated with aclarubicin or daunorubicin plus cytosine arabinoside followed by intensive consolidation chemotherapy in a Danish national phase III trialDE NULLY BROWN, P; HOFFMANN, T; HANSEN, O. P et al.Leukemia. 1997, Vol 11, Num 1, pp 37-41, issn 0887-6924Article

Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemiaGEISLER, C. H; LARSEN, J. K; ANDERSEN, P. K et al.Blood. 1991, Vol 78, Num 7, pp 1795-1802, issn 0006-4971Article

The bone-marrow infiltration pattern in B-cell chronic lymphocytic leukemia is not an important prognostic factorGEISLER, C. H; HOU-JENSEN, K; THORLING, K et al.European journal of haematology. 1996, Vol 57, Num 4, pp 292-300, issn 0902-4441Article

Multiple myeloma treated with mitoxantrone in combination with vincristine and prednisolone (NOP regimen) versus melphalan and prednisolone : a phase III studyKELDSEN, N; BJERRUM, O. W; LAMVIK, J et al.European journal of haematology. 1993, Vol 51, Num 2, pp 80-85, issn 0902-4441Article

In B-cell chronic lymphocytic leukaemia chromosome 17 abnormalities and not trisomy 12 are the single most important cytogenetic abnormalities for the prognosis : A cytogenetic and immunophenotypic study of 480 unselected newly diagnosed patientsGEISLER, C. H; PHILIP, P; ELLEGAARD, J et al.Leukemia research. 1997, Vol 21, Num 11-12, pp 1011-1023, issn 0145-2126Article

Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia : a danish national phase III trialPAASKE HANSEN, O; PEDERSEN-BJERGAARD, J; KILLMANN, S.-A et al.Leukemia. 1991, Vol 5, Num 6, pp 510-516, issn 0887-6924Article